STOCK TITAN

Xebra Provides Update on the Issuance of its Mexican Cannabis Authorizations

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

Xebra Brands Ltd. (CSE: XBRA) (OTCQB: XBRAF) has provided an update on cannabis authorizations for its Mexican subsidiary, Xebra Mexico. Following a court order, the Mexican Health Regulatory Agency (COFEPRIS) is expected to issue authorizations for the importation, cultivation, and processing of cannabis products, specifically those with low THC levels. These authorizations mark a precedent in Mexico’s cannabis landscape. Xebra is positioned to tap into opportunities in hemp and CBD products, with potential expansion in hemp plastics.

Positive
  • First cannabis authorizations in Mexico for Xebra Mexico.
  • Potential for entering the hemp and CBD markets.
  • Opportunities identified in the hemp plastics industry.
Negative
  • Authorization issuance has faced multiple court extensions.
  • Regulatory delays could impact operational timelines.

VANCOUVER, BC, Nov. 17, 2022 /PRNewswire/ - Xebra Brands Ltd. ("Xebra") (CSE: XBRA) (OTCQB: XBRAF) (FSE: 9YC), a cannabis company, provides an update on the issuance of its Mexican cannabis authorizations.

Xebra previously announced that it expected the issuance of cannabis authorizations to its Mexican subsidiary, Desart MX, SA de CV ("Xebra Mexico") in October. The Mexican Health Regulatory Agency (the Mexican FDA equivalent) (the "COFEPRIS"), has been officially ordered by the courts to grant the authorization. Since these are the first cannabis authorization in Mexico related to seed importation, cultivation, processing, and manufacturing; they are without legal precedent, hence the COFEPRIS has requested, and has been granted, extensions by the courts to issue the authorizations. The most recent extension expires in approximately two (2) weeks. Xebra and the COFEPRIS are working diligently with the aim of effecting the issuance of the authorizations as soon as possible.

Xebra Mexico's authorizations will apply specifically to cannabis with low-levels of THC (under 1%), therefore, in practical terms, to hemp cultivation and processing, and to the manufacture and sale of mainly CBD products, and certain uses of the cannabis flower. Opportunities in the hemp plastics industries have also been identified.

Jay Garnett
CEO

Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.'s expectations in respect of its ability to successfully execute its business plan or business model; its ability to provide economic, environmental, social, or any benefits of any type, in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Canada, or elsewhere, including cannabis authorizations from the Mexican Health Regulatory Agency (COFEPRIS) and the timing of such permits or authorizations; its ability to successfully apply for and obtain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to commercialize, cultivate, grow, or process hemp or cannabis in Mexico, Canada, or elsewhere and related plans and timing; its ability to manufacture, commercialize or sell cannabis-infused beverages, wellness products, or other products in Mexico, Canada, or elsewhere; its ability to launch, commercialize or to sell Vicious Citrus Lemonade or any additional cannabis infused beverage brands or products, at any time, in any jurisdiction, and its related plans and claims, including market interest and availability; its ability to commercialize or to sell Elements wellness products in any jurisdiction at any time; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; financial projections including expected revenues, gross profits, and EBITDA (which is a non-GAAP financial measure); plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management's expectations, beliefs and assumptions in general, including manufacturing costs, production activity and market potential in Mexico or any jurisdiction; events or developments that XEBRA expects to take place in the future; general economic conditions; and other risk factors described in the prospectus of the Company dated September 30, 2021. All statements, other than statements of historical facts, are forward-looking information and statements. The words "aim", "believe", "expect", "anticipate", "contemplate", "target", "intends", "continue", "plans", "budget", "estimate", "may", "will", and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by XEBRA as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of XEBRA to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete a potential acquisition for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; and the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approval for license applications. In addition, there is no assurance Xebra will: be a low-cost producer or exporter; obtain a dominant market position in any jurisdiction; have products that will be unique; launch other Vicious Citrus SKUs; or monetize any asset sales from its Colombian and Dutch subsidiaries. The foregoing list is not exhaustive and XEBRA undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect XEBRA's actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, XEBRA. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/xebra-provides-update-on-the-issuance-of-its-mexican-cannabis-authorizations-301680927.html

SOURCE Xebra Brands Ltd.

FAQ

What is the latest update on Xebra Brands Ltd.'s Mexican cannabis authorizations?

Xebra Brands announced that the Mexican Health Regulatory Agency must issue cannabis authorizations to its subsidiary Xebra Mexico, with extensions granted due to legal precedents.

When is the expected issuance date for Xebra's cannabis authorizations?

The most recent court extension regarding the issuance expires in approximately two weeks from the announcement date.

What types of cannabis products will Xebra be authorized to produce in Mexico?

Xebra's authorizations will specifically cover cannabis with low THC levels for hemp cultivation and CBD product manufacturing.

What challenges is Xebra facing in obtaining cannabis authorizations?

Xebra is experiencing delays due to the need for multiple extensions for the court-ordered issuance of authorizations by COFEPRIS.

What opportunities does Xebra see in the hemp market?

Xebra has identified potential in the hemp plastics industry alongside its core CBD product offerings.

XEBRA BRANDS LTD

OTC:XBRAF

XBRAF Rankings

XBRAF Latest News

XBRAF Stock Data

3.53M
27.22%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Vancouver